A-M Kirsten - JoVE Visualize

Showing results (1-10 of 6) with videos related to

Pageof 1

Sort By:

European Journal of Medical Research|August 28, 1997

Effect of a nasal challenge with endotoxin-containing swine confinement dust on nasal nitric oxide productionA M Kirsten, R A Jörres, D Kirsten, et al.

Pneumologie (Stuttgart, Germany)|April 1, 1997

[Comparison of nasal and bronchial production of nitric oxide in healthy probands and patients with asthma]A M Kirsten, R A Jörres, D Kirsten, et al.

Deutsche Medizinische Wochenschrift (1946)|March 26, 2008

[Heart failure in chronic obstructive pulmonary disease (COPD)]H Watz, B Waschki, A-M Kirsten, et al.

Pulmonary Pharmacology & Therapeutics|February 15, 2015

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPDA M Kirsten, K Förster, E Radeczky, et al.

BMJ Open Respiratory Research|December 10, 2016

Angiopoietin-like protein 4 and cardiovascular function in COPDB Waschki, A M Kirsten, O Holz, et al.

Pulmonary Pharmacology & Therapeutics|August 22, 2017

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPDA Cahn, J N Hamblin, M Begg, et al.

Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:

Pageof 1

European Journal of Medical Research|August 28, 1997

Effect of a nasal challenge with endotoxin-containing swine confinement dust on nasal nitric oxide productionA M Kirsten, R A Jörres, D Kirsten, et al.

Pneumologie (Stuttgart, Germany)|April 1, 1997

[Comparison of nasal and bronchial production of nitric oxide in healthy probands and patients with asthma]A M Kirsten, R A Jörres, D Kirsten, et al.

Deutsche Medizinische Wochenschrift (1946)|March 26, 2008

[Heart failure in chronic obstructive pulmonary disease (COPD)]H Watz, B Waschki, A-M Kirsten, et al.

Pulmonary Pharmacology & Therapeutics|February 15, 2015

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPDA M Kirsten, K Förster, E Radeczky, et al.

BMJ Open Respiratory Research|December 10, 2016

Angiopoietin-like protein 4 and cardiovascular function in COPDB Waschki, A M Kirsten, O Holz, et al.

Pulmonary Pharmacology & Therapeutics|August 22, 2017

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPDA Cahn, J N Hamblin, M Begg, et al.

Pageof 1